ENOV ENOVIS CORPORATION

Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions

Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions

Designed with our patented and proven NiTiNOL technology, DynaNail Helix™ revolutionizes dynamic compression in foot & ankle fusion

Wilmington, DE, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announces the introduction of the DynaNail Helix™, the latest addition to the DynaNail® family and Enovis’ expansive suite of foot and ankle products. DynaNail Helix is designed to achieve sustained dynamic compression for subtalar fusion with an innovative, anatomically friendly design and simple, screw-like insertion.

Leveraging the same groundbreaking NiTiNOL compressive element technology from other DynaNail systems, the DynaNail Helix is smaller, easy to use, and comes with expanded indications.

“This is the same NiTiNOL technology used in the DynaNail intramedullary system. It provides sustained compression across the fusion site, which traditional screws cannot do,” said Dr. Christopher Hirosei, a foot and ankle orthopedic surgeon based in Boise, Idaho. “The Enovis DynaNail Helix NiTiNOL implants are as easy to use as traditional screws.” 

DynaNail Helix’s NiTiNOL compressive element comes pre-stretched and pre-loaded on a disposable nail guide for maximum efficiency. Like a screw, its threads allow for easy insertion. There are no transverse screws, eliminating the need for orthopedic surgeons to stretch the compressive element manually.

“The flexible, pseudo elastic NiTiNOL element that DynaNail Helix offers is unlike typical static fixation devices that are available on the market. Not only does DynaNail Helix offer intraoperative manual compression, but it also allows for up to 4mm of post-operative compression in response to bone resorption or settling,” said Gary Justak, President of Enovis Foot & Ankle. “This sustained compression is designed to give patients a better chance at healing faster, with fewer complications.”

The DynaNail Helix is one of several new products introduced by Enovis Foot & Ankle this year with active, adaptive healing technology designed to improve patient outcomes across the continuum of care.

For more information on the new DynaNail Helix, visit .

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .

MK-10295






i Dr. Hirose is a paid consultant at Enovis.



Attachment



Media Contact:
Megan Foltz
Enovis
(609) 680-0996
 
EN
17/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Enovis Announces Third Quarter 2025 Results

Enovis Announces Third Quarter 2025 Results Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today annou...

 PRESS RELEASE

Enovis announces webcast and conference call for Third Quarter 2025 Re...

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch